Evaluation of cold plasma treatment technology in biosynthesized silver nanoparticles encapsulated with chitosan by Aliinostoc persicum SA14 against HepG-2

Hepatocellular carcinoma (HCC) is the commonest cancer and the third most common cause of cancer-related mortality. The combination of cold atmospheric plasma (CAP) and nanoparticles is a promising treatment for hepatocellular carcinoma cancers. In the present study, activated water was prepared using the cold atmospheric plasma technique (JET and PAW), and then the biosynthesis ability of silver nanoparticles by the cyanobacterium Aliinostoc persicum SA14 was measured after cultivation in the culture medium containing activated water at 5, 15, and 20 min. After the encapsulation of nanoparticles with chitosan and UV–visible spectroscopy analysis, the characterization of AgNPs, including FTIR analysis. X-ray diffraction, particle size and zeta potential, SEM, TEM, as well as cytotoxicity assays against HepG-2 cell lines, were performed. The comparison of the absorption spectra of silver oxide nanoparticles prepared by the boiling-dender method at concentrations and different times showed that the production of silver nanoparticles was confirmed for all three samples based on the amount of absorption obtained. The outcomes of field emission scanning electron microscopy at all magnifications exhibited that spherical nanoparticles are scattered on the surface of the polymer matrix. Furthermore, the FT-IR spectrum and XRD crystallography confirmed the success of chitosan's production of microcoated silver nanoparticles. The results of the cytotoxicity test against HepG-2 cell lines showed that with increasing concentrations of silver nanoparticles, the survival frequency of cancer cells declined significantly. In conclusion, the tests confirmed that the silver nanoparticles produced by cyanobacteria act as both a stabilizing and reducing agent. The results indicated that CAP decreases nanoparticle size, decreases surface charge distribution of AgNP, and induces uptake, aggregation, and enhanced cytotoxicity against HepG-2 in vitro. The chitosan-AgNPs with cold plasma could have potential applications in the food, agricultural, and pharmaceutical industries.